Rapafusyn Pharmaceuticals
United States
- Baltimore, Maryland
- 25/06/2024
- Series A
- $28,000,000
Rapafusyn Pharmaceuticals is an emerging pharmaceutical development company located in Baltimore Maryland. Rapafusyn has licensed technology related to a novel class of natural product-like macrocycles from Johns Hopkins University School of Medicine and seeks to develop novel pharmaceuticals to treat patients having diseases and fulfill unmet medical needs.
- Industry Research Services
- Website https://www.rapafusyn.com/
- LinkedIn https://www.linkedin.com/company/rapafusyn-pharmaceuticals/
Related People
Sean X. HuFounder
United States -
New York, New York
> A leader with a track record of successfully building teams and growing a business;
> A recognized world class thought leader in personalized medicine strategies for both drug and molecular diagnostic product development, commercialization and marketing, as well as corporate level personalized medicine strategies;
> A seasoned strategist for the life science industries (pharmaceutical, diagnostics, biotech and beyond), well experienced in product commercialization / global marketing, portfolio optimization, corporate organizational and growth strategies, licensing and corporate development;
> Unique combination of strategic consulting and hands-on, industry operational experience;
> Educated in both science and business, with a BS in Organic Chemistry, a PhD in Genomics, and an MBA double majored in Strategic and Entrepreneurial Management;
Vor Systems | $3,000,000 | (Mar 6, 2026)
IntelliGRC | $3,500,000 | (Mar 6, 2026)
Cyclops | $8,000,000 | (Mar 6, 2026)
Lio (formerly askLio) | $30,000,000 | (Mar 6, 2026)
Navigara | $2,500,000 | (Mar 6, 2026)
AgriPass | $7,500,000 | (Mar 6, 2026)
Reclaim Security | $20,000,000 | (Mar 6, 2026)
NextWork | $4,450,000 | (Mar 6, 2026)
Vast | $500,000,000 | (Mar 6, 2026)
Qura | $1,739,595 | (Mar 4, 2026)
Escargot | $2,750,000 | (Mar 4, 2026)
Worldscape | Undisclosed Amount | (Mar 4, 2026)